COMP <GO>
CX vs TMO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Cemex S.A.B. de C.V. Sponsored ADR (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CX 6
— TMO 7
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: TMO
LAST: $10.70 (-1.20%) • MKT CAP: $16.42B
options-implied-move
6.90%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
options-implied-move
6.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.30% | +0.60 | CX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 30.4x | -9.40 | CX | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 2.40% | -0.19 | TMO | /fcf-yield <GO> |
| Operating Margin | 13.90% | 17.40% | -3.50 | TMO | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 15.10% | -4.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 3.90% | +7.10 | CX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 4.50 | -0.76 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.4 | 59.1 | +2.24 | CX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.94 | +0.05 | CX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 36.3x | -5.80 | CX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.42B | $262.22B | -$245.80B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CX REV | TMO REV | CX GROSS % | TMO GROSS % | CX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $44.56B | — | 44.0% | — | $6.29B |
| FY 2024 | — | $42.88B | — | 44.0% | — | $7.27B |
| FY 2023 | — | $42.86B | — | 44.0% | — | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CX // BETA 0.99
TMO // BETA 0.94